Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

Mistrust in health care and government could explain COVID-19 vaccine hesitancy among Black women in the United States.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

According to a recent study, there have been shifts in both the patterns and correlates of ketamine use from 2015 to 2022.

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

There is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up across populations.

Postdischarge contacts with patients after hospitalization not associated with reductions in emergency department use or readmissions.

The US FDA has amended its color additive regulations to no longer allow the use of FD&C Act Red No. 3 in food and ingested drugs.

Sex-related differences in pulmonary complications were found among men vs women with SSc, specifically in the prevalence of ILD and SAD.

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Historical redlining is linked to care utilization and fragmentation among patients with rheumatic conditions, highlighting the role of structural racism in these disparities.

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.